TRCT
OCRX

Tower Research Capital (TRC)’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-800
Closed -$1K – 3939
2017
Q1 		$1K Buy
800
+100
+14% +$127 ﹤0.01% 2931
2016
Q4 		$1K Buy
700
+300
+75% +$700 ﹤0.01% 3736
2016
Q3 		$1K Buy
400
+57
+17% +$142 ﹤0.01% 3481
2016
Q2 		$1K Sell
343
-168
-33% -$442 ﹤0.01% 4314
2016
Q1 		$2K Sell
511
-2,431
-83% -$6.94K ﹤0.01% 3553
2015
Q4 		$9K Buy
+2,942
New +$10.1K ﹤0.01% 2346
2015
Q3 		– Sell
-257
Closed -$1K – 5270
2015
Q2 		$1K Sell
257
-6
-2% -$23 ﹤0.01% 4182
2015
Q1 		$1K Buy
+263
New +$1.52K ﹤0.01% 4251
2014
Q4 		– Sell
-309
Closed -$2K – 5135
2014
Q3 		$2K Sell
309
-719
-70% -$4.15K ﹤0.01% 3956
2014
Q2 		$8K Sell
1,028
-113
-10% -$901 ﹤0.01% 2561
2014
Q1 		$12K Buy
1,141
+533
+88% +$7.62K ﹤0.01% 2470
2013
Q4 		$8K Sell
608
-184
-23% -$1.72K ﹤0.01% 3239
2013
Q3 		$7K Buy
+792
New +$6.38K ﹤0.01% 3494

Other funds holding OCRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tower Research Capital (TRC)'s OCRX Position: Q2 2017 in Review

Tower Research Capital (TRC) sold out of Ocera Therapeutics, Inc. (OCRX) in Q2 2017, closing a stake of 800 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in OCRX in Q3 2013 and held it in 13 quarters. The position peaked at $12K in Q1 2014. 24 funds tracked by Wall St. Rank hold OCRX as of Q2 2017.

  • Tower Research Capital (TRC) reported no remaining Ocera Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 800 Ocera Therapeutics, Inc. shares in Q2 2017, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in Ocera Therapeutics, Inc. in Q3 2013 and held it in 13 quarters.
  • Tower Research Capital (TRC)'s Ocera Therapeutics, Inc. position peaked at $12K in Q1 2014.
  • 24 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q2 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2017, filed 15 Aug 2017.